General Information:
Id: | 1,989 (click here to show other Interactions for entry) |
Diseases: |
Cardiovascular disease
Diabetes mellitus, type II - [OMIM] Insulin resistance Myocardial infarction - [OMIM] Nephropathy, diabetic Neuropathy, diabetic Retinopathy, diabetic Stroke, ischemic - [OMIM] |
Mammalia | |
review | |
Reference: | Lardizabal JA and Deedwania PC(2010) The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus Curr Cardiol Rep 12: 464-471 [PMID: 20809236] |
Interaction Information:
Comment | In patients with IGT, both early and late phases of insulin secretory responses are abnormal, leading to prolonged hyperglycemia after a glucose load. In those with isolated IFG, there is reduction in the early phase of insulin secretory response, which causes fasting hyperglycemia; however, the late phase response is preserved, which allows the normalization of blood sugar levels after a glucose load. |
Formal Description Interaction-ID: 15638 |
phenotype affects_activity of process |
Comment | In patients with IGT, both early and late phases of insulin secretory responses are abnormal, leading to prolonged hyperglycemia after a glucose load. In those with isolated IFG, there is reduction in the early phase of insulin secretory response, which causes fasting hyperglycemia; however, the late phase response is preserved, which allows the normalization of blood sugar levels after a glucose load. |
Formal Description Interaction-ID: 15640 |
phenotype affects_activity of process |
Comment | The protection afforded by ARBs against the deleterious effects of inflammatory and oxidative stress was associated with increased beta-cell mass, augmented insulin secretion, and improved glucose tolerance. Furthermore, ARB therapy was also shown to prevent the loss of endothelial cells and reduce fibrosis in and around the islets. |
Formal Description Interaction-ID: 15692 |
drug/chemical compound Angiotensin II type 1 receptor blocker decreases_activity of process |